Navigation Links
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
Date:7/17/2014

erfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us and our partners to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products (including products of our wholly-owned subsidiaries) are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products a
'/>"/>

SOURCE Amgen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
2. Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference
3. Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
4. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
5. Amgen Announces 2014 First Quarter Dividend
6. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
7. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
8. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
9. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... N.J. , Sept. 19, 2014 Merck (NYSE: ... States and Canada , is teaming ... Desafiando La Diabetes: Logra Tus Metas , an educational program encouraging ... blood sugar -- a key treatment goal to help reduce the ... States are at a higher risk for developing type ...
(Date:9/19/2014)... R.I. , Sept. 19, 2014 Larry ... CVS ), will speak before the National Press ... will discuss the company,s recent move to stop selling tobacco ... shape the future of health. "Dramatic changes in ... health care providers and government," Merlo has said. "CVS Health ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... , , LACHEN, Switzerland and HOBOKEN, N.J., ... m a AG is leading an ... therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, ... from a human cell line, could dramatically impact the treatment of an ...
... , , , ... AMGN ) today announced that in a large, randomized, double-blind, placebo-controlled, ... requiring dialysis), anemia and type-2 diabetes (the T rial to ... T herapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin ...
Cached Medicine Technology:Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 2Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 3Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 4Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 2Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 3Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 6Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 7Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 8
(Date:9/20/2014)... Ticket Down is a reputable ... her 2015 “Honeymoon Tour.” This well-known ticket exchange is ... , In early 2015, fans will have a chance to ... North America. Twenty-one-year-old Ariana Grande will hit the road in ... to 25 cities across the United States and Canada. Grande, ...
(Date:9/20/2014)... The excitement is building up once again for the ... This year the Surry Arts Council will be celebrating its 25th ... who are still fans of the Andy Griffith Show. ... on CBS from 1960 through 1968. The show ranked by ... Mount Airy, North Carolina is where the show was filmed ...
(Date:9/20/2014)... September 20, 2014 Earlier this week, Home ... may have had their credit card information pilfered by hackers, ... a slew of headline articles like this one ... only eye opening numbers. , “Most people tend to ... like it’s a way to score a game,” says Joe ...
(Date:9/20/2014)... 2014 The first federal bellwether trial ... its third week in the U.S. District Court, Northern ... documents indicate that the week opened in the ... a DePuy Orthopaedics vice president, who discussed the clinical ... Pinnacle hip replacement. According to Reuters, the executive stated ...
(Date:9/19/2014)... 2014 Consistent premium price increases ... Vision Insurance industry in recent years; however, costs ... industry margins. From 2009 to 2014, industry revenue ... coverage for routine eye exams and other procedures, ... lens and refractive surgery. According to IBISWorld Industry ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4
... symptoms of grief linger and become increasingly debilitating. This ... and post-traumatic stress disorder (PTSD). // And there ... may bring relief, reports the October issue of the ... symptoms of complicated grief are intrusive thoughts of the ...
... the South Australian Government’s decision to review the types of ... SA Government says it’s concerned that chips, lollies, chocolate and ... vending machines and canteens. ,Dr Haikerwal said many ... ,“Hospitals should make healthy food the easy option,” ...
... staff working the night shift could benefit from a ... research has revealed. // ,In their editorial ... Professor Doug McEvoy and Professor Leon Lack of Flinders ... short periods of shut-eye for medical staff working through ...
... the University of Washington, in Seattle, a group of engineers ... latest creation: a surgical robot// to deploy in far-flung places, ... ,Military groups all over the world have long ... time often decides who lives and who dies. A recent ...
... Children's Research Hospital have discovered that a protein called ABCB6 ... is key to the ability// of red blood cells to ... of cells to extract energy from nutrients. ,The ... outer membrane of the cell’s energy powerhouse called the mitochondria; ...
... the good news: Suicide rates among younger and older Americans ... news: No one really knows why// . ,Those ... the University of South Carolina and released Thursday (Sept. 28) ... Health. ,Dr. Robert McKeown, a professor and associate ...
Cached Medicine News:Health News:Power Naps to Fight Night-shift Fatigue 2Health News:Doc at a Distance 2Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3
Precision near-field imaging combined with the best handling IVUS catheter....
Premium Full Color Digital Ultrasound...
... VH series, it is a ... independent C-arms and image intensifiers, ... for Cardiovascular and Angiography. There ... the examinations for cerebral, cardiac, ...
This catheter is intended for ultrasound examination of coronary intravascular pathology only. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Medicine Products: